Browsed by
Tag: Shareholders

Would Shareholders Who Purchased Infinity Pharmaceuticals’ (NASDAQ:INFI) Stock Five Years Be Happy With The Share price Today?

Would Shareholders Who Purchased Infinity Pharmaceuticals’ (NASDAQ:INFI) Stock Five Years Be Happy With The Share price Today?

It is a pleasure to report that the Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) is up 42% in the last quarter. But will that repair the damage for the weary investors who have owned this stock as it declined over half a decade? Probably not. Like a ship taking on water, the share price has sunk 87% in that time. The recent bounce might mean the long decline is over, but we are not confident. The real question is whether the business can leave its past behind and improve itself over the years ahead.

We really feel for shareholders in this scenario. It’s a good reminder of the importance of diversification, and it’s worth keeping in mind there’s more to life than money, anyway.

Check out our latest analysis for Infinity Pharmaceuticals

We don’t think Infinity Pharmaceuticals’ revenue of US$1,438,000 is enough to establish significant demand. This state of affairs suggests that venture capitalists won’t provide funds on attractive terms. As a result, we think it’s unlikely shareholders are paying much attention to current revenue, but rather speculating on growth in the years to come. For example, they may be hoping that Infinity Pharmaceuticals comes up with a great new product, before it runs out of money.

We think companies that have neither significant revenues nor profits are pretty high risk. There is almost always a chance they will need to raise more capital, and their progress – and share price – will dictate how dilutive that is to current holders. While some such companies do very well over the long term, others become hyped up by promoters before eventually falling back down to earth, and going bankrupt (or being recapitalized). Infinity Pharmaceuticals has already given some investors a taste of the bitter losses that high risk investing can cause.

Infinity Pharmaceuticals

Read the rest
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in BioMarin Pharmaceuticals, Inc. of

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in BioMarin Pharmaceuticals, Inc. of

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on
their Investment in BioMarin Pharmaceuticals, Inc. of Class Action Lawsuit and
Upcoming Deadline – BMRN

NEW YORK, Oct.  08, 2020 (GLOBE  NEWSWIRE) -- Pomerantz  LLP announces that  a
class action lawsuit  has been  filed against  BioMarin Pharmaceuticals,  Inc.
 (“BioMarin” or the “Company”)  (NASDAQ: BMRN) and  certain of its  officers. 
The class  action, filed  in United  States District  Court for  the  Northern
District of California,  and docketed  under 20-cv-06719,  is on  behalf of  a
class consisting  of  all  persons  other than  Defendants  who  purchased  or
otherwise, acquired BioMarin securities between  February 28, 2020 and  August
18, 2020,  both  dates inclusive  (the  “Class Period”),  seeking  to  recover
damages caused by Defendants’ violations of the federal securities laws and to
pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange  Act
of 1934 (the “Exchange  Act”) and Rule  10b-5 promulgated thereunder,  against
the Company and certain of its top officials.

If you are a  shareholder who purchased BioMarin  securities during the  class
period, you have until November 24, 2020,  to ask the Court to appoint you  as
Lead Plaintiff for  the class.  A  copy of  the Complaint can  be obtained  at
www.pomerantzlaw.com.  To discuss this action, contact Robert S. Willoughby at
newaction@pomlaw.com or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext.  7980.
Those who inquire by e-mail are  encouraged to include their mailing  address,
telephone number, and the number of shares purchased. 

         [Click here for information about joining the class action]

BioMarin is a biotechnology company that develops and commercializes therapies
for people  with  serious  and  life-threatening  rare  diseases  and  medical
conditions.  The   Company’s  product   candidates  include,   among   others,
valoctocogene roxaparvovec, an investigational adeno-associated virus  (“AAV”)
gene therapy, which is  in Phase 3 clinical  development for the treatment  of
patients with severe hemophilia A.

Based 
Read the rest